Introduction
Enterococci as a cause of nosocomial infection have become more prevalent over the last 20 years, both in the USA and in Western European countries. Strains of enterococci have acquired resistance to almost all antimicrobial agents, including vancomycin.
Vancomycin-resistant Enterococcus (VRE) was first isolated in the UK and France in 1986, 1 and one year later, Objective: To characterize the mechanism of glycopeptide resistance and to determine the genetic relatedness among strains by pulsed-field gel electrophoresis (PFGE) in vancomycinresistant Enterococcus faecium from Argentina. Materials and methods: A total of 189 vancomycin-resistant single-patient isolates of Enterococcus faecium recovered between January 1997 and December 2000 from 30 hospitals in Argentina were studied. Minimum inhibitory concentrations were determined by the agar dilution method and van genes were detected by PCR. PFGE was used for molecular typing. Results: All isolates except three (vanB) were of genotype vanA. For 189 vancomycin-resistant Enterococcus faecium, SmaI-PFGE indicated 35 clonal types. Most of the isolates (56%) belonged to the same clonal type 1, which was present in 19 hospitals and dominant in 17. Conclusions: The emergence of vancomycin-resistant Enterococcus faecium in Argentina seems to be related to the intra-and inter-hospital dissemination of an epidemic clone carrying the vanA element. # 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
the first cases of VRE were documented in the USA. 2 Important differences in the epidemiology of VRE in the USA and Europe were observed. In the USA, the major factor contributing to the dissemination of VRE was the excessive use of glycopeptides and other antibiotics in the healthcare environment. In contrast, in Europe the emergence of VRE took place outside hospitals. A large reservoir of transferable vanA gene cluster was identified in animal husbandry and has been associated with the use of avoparcin as a growth promoter in animal feed. [3] [4] [5] Nowadays, VRE are distributed worldwide. The incidence of VRE infection in the USA has greatly increased over the past 15 years. Within 10 years VRE represented more than 25% of enterococci associated with bloodstream infections in hospitalized patients in the USA. 6 In Latin America, VRE have been reported in Brazil 7 and Colombia. 8 In Argentina, the first reported VRE, an Enterococcus faecium isolate carrying the vanA gene, was isolated in 1997 from a blood culture. 9 After that, many hospitals in our country implemented a survey of stool or rectal swab cultures in order to detect VRE colonization and to prevent and control nosocomial transmission.
Between January 1997 and December 2000, at the Antimicrobial Division of the National Institute of Infectious Diseases (INEI) ''Dr. C.G. Malbrán'', we received a total of 189 vancomycin-resistant E. faecium from 30 hospitals. Almost all Argentinean hospitals that had identified vancomycin-resistant E. faecium up to December 2000 contributed their isolates to this study. The main objectives of the present study were to characterize the mechanisms of glycopeptide resistance and to evaluate the mode of dissemination of vancomycin-resistant E. faecium isolates in Argentina.
Materials and methods

Clinical isolates
From January 1997 to December 2000, 189 vancomycinresistant E. faecium from 30 hospitals were received at the INEI to confirm the genotype. Eleven enterococci (5.8%) were recovered during 1997, 49 (25.9%) in 1998, 67 (35.5%) in 1999, and 62 (32.8%) in 2000. Isolates were identified in each hospital to the species level with conventional biochemical tests as described by Carvalho et al. 10 One hundred and twenty-five (66.1%) isolates were collected from 20 hospitals in Buenos Aires City, 52 (27.5%) from six hospitals in the Province of Buenos Aires, three (1.6%) from two hospitals in the Province of Córdoba (700 km from Buenos Aires City), seven (3.7%) from one hospital in the Province of Chaco (970 km from Buenos Aires City), and two (1.1%) from one hospital in the Province of Santa Fe (480 km from Buenos Aires City). Names, locations, and the number of isolates recovered from each hospital are listed in Table 1 .
Vancomycin-resistant E. faecium strains were isolated from rectal swabs in 145 (76.7%), urine in 17 (9%), blood in nine (4.8%), and from other sources in 18 (9.5%). Only the initial isolate of each patient was included in the study. Most of the strains were isolated in the intensive care units (ICU) (46.5%) and general medicine wards (36%). One hundred and fifty-two patients (80.4%) were colonized with VRE, 28 (14.8%) exhibited signs of clinical infection, and in nine (4.8%) cases an assessment of the clinical significance was not possible.
Antimicrobial susceptibility
Minimum inhibitory concentrations (MICs) to ampicillin (Bagó Argentina), vancomycin (Lilly), teicoplanin (Aventis Pharma), gentamicin (Schering-Plough), streptomycin (Rontag), tetracycline (Phoenix), chloramphenicol (Parke Davis), erythromycin (Lilly), and ciprofloxacin (Roemmers Argentina) were determined by the agar dilution procedure according to the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) recommendations. 11, 12 Quality control strains used were Staphylococcus aureus ATCC 29213, E. faecalis ATCC 29212, and E. faecalis ATCC 51299.
PCR amplification of glycopeptide resistance genes
The presence of van genes was detected by PCR using specific primers for vanA and vanB and conditions already described. 13 DNA template was prepared by the boiling method. Reactions were performed with a Biometra thermal cycler (Whatman Biometra GmbH, Göttingen, Germany). The PCR amplification products were analyzed in 1% agarose gel. E. faecalis vanA Tx2403 and E. faecium vanA WHO-3 used as positive controls, were kindly provided by Barbara Murray (University of Texas at Houston, USA) and Fred Tenover (CDC, Atlanta, GA, USA), respectively. Specific primers for the 16S ribosomal RNA gene were used as controls of DNA extraction. 14 Amplification of the intergenic vanS-vanH region was performed using the specific primers, vanS-f (forward) and vanH-r (reverse), as described by Brown et al. 15 PCR-RFLP was performed on vanSH amplicons, using HindIII and EcoRI enzymes as recommended by the manufacturer (New England Biolabs, Beverly, MA, USA).
PFGE typing
Isolates were grown overnight in brain-heart infusion broth. Chromosomal DNA was prepared in agarose plugs and subjected to endonuclease digestion with SmaI (New England Biolabs, Beverly, MA, USA) as previously described. 16 DNA fragments were separated in 0.8% agarose using a CHEF-DRIII apparatus (Bio-Rad Laboratories, Richmond, CA, USA), with running conditions of 6 V/cm and pulses ranging from 5 to 35 seconds during 26 h at 7 8C. Lambda ladder (New England Biolabs) was used as molecular size standard. Gels were stained with 1 mg/mL ethidium bromide and photographed under UV illumination. The similarity between isolates was determined by visual comparison of isolate banding patterns. The interpretation of the band patterns was carried out according to previously published guidelines. 17 Isolates were defined as distinct strain types, or unrelated, if their PFGE patterns differed by more than six bands. Types were named using a consecutive Arabic number (e.g. type 1, 2, 3). Subtypes were defined as strains that differed by 2-6 bands, which were considered closely or possibly related, and were named using a letter following the Arabic number (e.g. subtype 1a, 1b, 1c). Those isolates whose restriction patterns had the same number and size of bands were considered genetically indistinguishable and were assigned to the same strain type and subtype. 
Results and discussion
The emergence of VRE is a serious nosocomial problem with important implications for hospital infection control.
Among the 189 isolates characterized in this study, 186 (98%) carried the vanA gene and only three the vanB gene ( Table 1 ). All vanA E. faecium showed high-level resistance to vancomycin (MICs 32-512 mg/L) and teicoplanin (MICs 8-64 mg/L), which is characteristic of the vanA phenotype. The three isolates with the vanB phenotype showed MICs of 16-32 mg/L for vancomycin and 0.12-1 mg/L for teicoplanin as we described in a previous study. 18 A predominance of E. faecium with the vanA genotype, as well as the predominance of vanA over vanB observed in our study have been previously described in VRE 6, 7, 19, 20 and may be related to the less efficient mobilization of the vanB complex. 16 However, we cannot dismiss the possibility that the ratio between vanA and vanB genes could be biased by the detection methods used in the primary laboratories.
Enterococci are intrinsically resistant to many antimicrobial agents, including cephalosporins, low concentrations of aminoglycosides, and trimethoprim-sulfamethoxazole. Furthermore, the ability of enterococci to acquire resistance to other agents like erythromycin, rifampin, chloramphenicol, ciprofloxacin, high concentrations of aminoglycosides, and vancomycin is well recognized. Consequently, treatment of VRE blood stream infections is a clinical challenge of great concern. In our collection the percentage of resistance was, as expected, high for vancomycin (100%), teicoplanin (97.9%), ampicillin (98.4%), erythromycin (100%), ciprofloxacin (98.9%), gentamicin (77.2%), and streptomycin (95.8%), but relatively low for tetracycline (6.3%) and chloramphenicol (3.7%). Antimicrobial resistance profiles with MIC 50 and MIC 90 are shown in Table 2 . These results are similar to those previously reported by Sader et al. in Brazil. 19 The analysis of molecular typing demonstrated 35 PFGE patterns among the 189 vancomycin-resistant E. faecium isolates, as shown in Figure 1 . One hundred and six isolates (56%) belonged to the most frequent clone 1, which was The presence of a dominant vancomycin-resistant E. faecium clone (clone 1) in 17 of 30 hospitals shows that their spread has occurred not only within individual hospitals but also between hospitals of various geographic locations. Other studies have documented the spread of vancomycin-resistant E. faecium 19, [21] [22] [23] and E. faecalis [24] [25] [26] clones among hospitals. In the present study, molecular typing results indicate the clonal dissemination of vancomycin-resistant E. faecium clone 1 in different wards of the same hospital, in different hospitals, and in different cities. The absence of an ongoing alert system for patients infected or colonized with vancomycin-resistant enterococci upon hospital readmission in our country may have contributed to this dissemination.
In some hospitals we observed a high number of clone 1 subtypes. In hospital COS there were 11 subtypes of the clone 1 and in hospital DUR six subtypes. The number of subtypes of a particular clone may reflect the evolution of the clone in a region and its relative age. Mutations, chromosomal rearrangements, as well as loss and acquisition of plasmids, transposons, or insertion sequences could be responsible for observed changes in PFGE profiles, resulting in different clonal subtypes. Probably, an epidemic clone that has persisted for a long time in a hospital subjected to an intensive selective pressure had a higher chance of incorporating more rearrangements in its genetic background than a non-epidemic clone.
Transposon Tn1546 was the first element described to carry the vanA cluster. 27 Tn1546 is highly heterogeneous, because of the occurrence of deletions, insertions, and point mutations. 16, 28 Although these events originated different vanA elements, they could derive from a unique ancestral Tn1546. 29 De Lencastre et al. reported that the occurrence of IS1251 is indicative of the presence of a larger transposon (26 kb) named Tn5482. 16 The insertion sequence IS1251 was found in the intergenic vanS-vanH region, mainly in isolates from the USA. 16, 28 We selected one representative isolate Vancomycin-resistant Enterococcus faecium in Argentina from each of the 33 vanA clonal types identified in this study, and determined the presence of IS1251 by PCR of the intergenic region vanS-vanH. All 33 isolates carrying the vanA gene yielded an 1871 bp amplimer when vanS-f and vanH-r primers were used, suggesting the presence of an IS1251-like element. The analysis of the 1871 bp amplimer by endonuclease digestion with HindIII and EcoRI resulted in the same RFLP profile as expected from the reported sequence (Genbank accession numbers: Tn1546, M97297 and IS1251, L34675) (data not shown). These results indicate the presence of IS1251 in the intergenic region vanS-vanH and suggest the possible horizontal dissemination of vanA through Tn5482. Recently we described the transfer of the vanA element by conjugation from highly resistant E. gallinarum isolates, carrying Tn5482, to vancomycin-susceptible E. faecium. 30 The most common clinical impact of VRE is intestinal colonization, which may persist for long periods. 31 Colonized individuals are potential reservoirs for transmission of VRE and should be identified and included in infection control interventions, because they constitute a major route of exposure. 32 Transmission is mediated by factors such as patient characteristics, antimicrobial use, and the prevalence of VRE within the hospital. 20 A large number of clinical studies have described the association of VRE colonization or infection with the use of vancomycin, antibiotics with activity against anaerobes, and extended-spectrum cephalosporins. 20, 31, 33 Recent reports of three vancomycinresistant S. aureus 34, 35 and the already demonstrated horizontal transfer of the vanA gene from vancomycin-resistant E. faecalis to Staphylococcus aureus, underscores the importance of understanding VRE epidemiology. 36 The emergence of predominant clonal types among multiple strains in several institutions of the survey, may suggest that some strains contain bacterial factors that enhance their spread within hospitals. Recently, Shankar et al. and Willems et al. have identified the esp gene encoding a surface protein associated with virulence for E. faecalis 37 and E. faecium, 38 residing on a pathogenicity island. 37, 39 Several authors have reported that the esp gene is not associated with vancomycin resistance. 40, 41 On the other hand, Harrington et al. support the hypothesis that in a clinical setting in which vancomycinresistant E. faecium is endemic, the combination of vancomycin resistance and the esp gene could lead to dissemination of particular clones. Recently, Willems et al. have identified a genetic lineage of E. faecium, named complex-17, associated with hospital outbreaks in five continents, representing the first globally dispersed nosocomial clonal lineage. 42 The subsequent acquisition of vanA or vanB genes for the hospitaladapted complex-17 resulted in vancomycin-resistant E. faecium with pandemic potential. In this way, it is probable that in Argentina a particular E. faecium clone has been selected and has adapted well to the hospital environment with the ability to spread. Although the presence of the esp gene was not assessed in the present study, we cannot dismiss the role of this factor in the spread of dominant clones. Further studies are necessary in order to investigate the presence of esp or other genes belonging to pathogenicity islands. Moreover, additional studies on the relation between the epidemic clone 1 and complex-17 lineage would be valuable in elucidating the epidemicity of this clone.
In summary, our results strongly suggest that intra-and inter-hospital spread of an epidemic vancomycin-resistant E. faecium clone carrying the vanA element seems to be the main mechanism of vancomycin-resistance dissemination in Argentina.
